5AM Ventures Announces Senior Leadership Appointments
MENLO PARK, Calif., January 9, 2014-- 5AM Venture Management, LLC (5AM) of Menlo Park, CA and Waltham, MA is pleased to announce the promotion of Kush M. Parmar, M.D., Ph.D. to Partner and the addition of Peter S. Kim, Ph.D. as a Venture Partner.
“We’re delighted to recognize the many contributions Kush has made to the 5AM team,” said Scott Rocklage, Ph.D., Managing Partner. “He has brought significant value to our firm with his extensive scientific understanding of medicine combined with his strong leadership skills and sound investment judgment.”
Dr. Parmar joined 5AM Ventures in 2010 from Harvard Medical School, where he was an NIH-sponsored M.D./Ph.D. Physician Scientist Fellow in the joint Harvard-MIT Health Sciences and Technology Program. He holds an A.B. in Molecular Biology and Medieval Studies from Princeton University, a Ph.D. in Experimental Pathology from Harvard University and an M.D. from Harvard Medical School.
Before joining 5AM, Dr. Parmar completed clinical clerkships at the Massachusetts General & Brigham and Women’s Hospitals, attended courses at Harvard Business School and consulted for an oncology startup. Dr. Parmar’s doctoral work at Harvard focused on cardiovascular biology and was published in The Journal of Clinical Investigation and the Journal of Biological Chemistry, among others.
Kush currently serves or has served as a Director or Observer on the Boards of Achaogen, Arvinas, Audentes Therapeutics, Cleave Biosciences, Envoy Therapeutics (acquired by Takeda), Novira Therapeutics and Pulmatrix. He is also a Fellow of the Kauffman Fellows Society.
Dr. Kim joined 5AM Ventures as a Venture Partner in 2014. He serves as Professor of Biochemistry at Stanford University School of Medicine and as Member of the Stanford Institute for Chemical Biology. He is a member of the Board of Trustees of the Alfred P. Sloan Foundation, the Board of Scientific Governors of The Scripps Research Institute, and the Scientific Review Board of the Howard Hughes Medical Institute (HHMI). A structural biologist known for discovering how proteins cause viral membranes to fuse with cells, he has designed compounds that stop membrane fusion by the AIDS virus, and has pioneered efforts to develop an HIV vaccine based on similar principles.
“Peter Kim is a rare indvidual who has demonstrated life science leadership as an academic researcher and as a large pharmaceutical company executive,” said John Diekman, Ph.D., Managing Partner. “He has been a friend to 5AM for many years and we look forward to working more closely with Peter as we identify new investments for 5AM Ventures IV.”
Dr. Kim was President of Merck Research Laboratories from 2003 – 2013. During his tenure, Merck gained approval of more than twenty new medicines and vaccines. These include JANUVIA, the first DPP-4 inhibitor for type 2 diabetes; GARDASIL, the first vaccine for prevention of cervical cancer; ISENTRESS, the first HIV integrase inhibitor; ZOSTAVAX, the first vaccine for the prevention of shingles in adults; ROTATEQ, an oral vaccine for the prevention of rotavirus infection in infants; and VICTRELIS, the first hepatitis C protease inhibitor. Previously, Dr. Kim was Professor of Biology at MIT, Member of the Whitehead Institute and Investigator of the HHMI. He was elected a member of the National Academy of Sciences in 1997, and is also an elected member of the Institute of Medicine and the American Academy of Arts and Sciences. Dr. Kim received his A.B. in Chemistry from Cornell University and his Ph.D. in Biochemistry from Stanford University.
About 5AM Ventures
Founded in 2002, 5AM Ventures actively invests in next-generation life science companies. The firm recently closed 5AM Ventures IV, L.P., a $250 million venture capital fund. With over $685 million under management, 5AM has invested in 40 early-stage companies and its successful exits include Alexza Pharmaceuticals (Nasdaq: ALXA), Envoy Therapeutics (sold to Takeda), Ilypsa (sold to Amgen), Incline Therapeutics (sold to The Medicines Company), KaloBios (Nasdaq: KBIO), Marcadia (sold to Roche), Miikana Therapeutics (sold to EntreMed), Panomics (sold to Affymetrix), Pearl Therapeutics (sold to AstraZeneca), Relypsa (Nasdaq: RLYP), Semprus (sold to Teleflex) and Synosia Therapeutics (sold to Biotie Therapies). For more information, please visit www.5amventures.com.
5AM Venture Management, LLC
Andy Schwab, Managing Partner
Venture Capital Database